Peptide education
Acetyl hexapeptide-8
Argireline · Acetyl hexapeptide-3 · Acetyl hexapeptide-8 amide
Acetyl hexapeptide-8 is a synthetic peptide used in creams and serums for the appearance of facial lines. It is also known as Argireline and was previously listed as acetyl hexapeptide-3.
Small studies of creams, serums, and patches have reported mixed results. The product and its delivery method matter, and one study's printed peptide sequence differs from the ingredient specification.
Overview
Quick answer
Laboratory effects on protein complexes involved in transmitter release do not establish that a cream relaxes facial muscles. Skin delivery and the performance of a finished formulation are separate questions.
Does it improve wrinkles?
Results vary. A study of a product called Argireline reported improved wrinkle assessments, but printed a different peptide sequence from the ingredient specification. A serum comparison found no significant difference; a separate patch comparison reported improvement on some measures.
Is it the same as botulinum toxin?
No. The peptide and botulinum toxin are different substances. Laboratory experiments on the peptide do not show an equivalent clinical effect.
What is known about safety?
A cosmetic safety panel assessed acetyl hexapeptide-8 amide as safe in the described uses at concentrations up to 0.005%. It found insufficient data to determine safety above that concentration.
Evidence
Evidence snapshot
The Argireline group showed improved assessments, but the paper's printed sequence differs from the ingredient specification.
The peptide-containing side did not differ significantly from the other side.
A laboratory test on donated skin detected no peptide in the deeper skin layer for the tested emulsion.
A peptide patch performed better than a plain patch on some eye-area wrinkle measures.
The panel's conclusion applies to the stated cosmetic conditions of use.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| The peptide reliably reduces expression lines. | Studies of different products have reported mixed results. One serum comparison found no significant difference between the two sides. | Laboratory experiments measured effects on a protein complex involved in transmitter release. A separate skin experiment found limited penetration. | Results are mixed and cannot be generalized to every product. |
| A serum has the same effect as botulinum toxin. | The cited cosmetic studies did not establish equivalent effects. | A laboratory finding does not show muscle relaxation after skin application. | The substances, delivery methods, and clinical evidence differ. |
Bottom line
Main takeaway
A peptide serum may be marketed for facial lines, but study results are mixed.
The peptide concentration, other ingredients, and delivery system can differ from those tested.
Compare the comparator, measurements, concentration disclosure, and follow-up for each formulation.
Identity
What it is
The six-residue peptide is patterned on part of SNAP-25, a protein involved in the release of chemical signals from cells.
Cosmetic labeling may use the name acetyl hexapeptide-8. The expert assessment treats acetyl hexapeptide-8 amide as synonymous with that name.
The ingredient specification lists a sequence starting with Glu-Glu. The randomized Argireline paper prints Gly-Glu instead. The reason for the discrepancy and the identity of the tested material are not established.
Research
Research evidence
Small studies evaluated eye-area wrinkles with creams, a serum, and a dissolving patch. Their findings do not show a consistent effect across products. The Argireline emulsion paper also prints a conflicting sequence.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Randomized placebo-controlled study | 60 Chinese participants with eye-area wrinkles | Randomized 3 to 1 to peptide or placebo for four weeks | Oil-in-water emulsion described as containing 10% Argireline | The authors reported better visual assessments and decreased roughness within the Argireline group. | The paper prints a different sequence from the ingredient specification, does not clarify the concentration basis, and reports within-group roughness tests rather than a direct between-group roughness test. | Limited human evidence |
| Double-blind split-face study | 19 women | Four-week comparison of opposite sides of the face | Hyaluronic-acid serum with the peptide on one side and without it on the other | Wrinkle-score differences between the sides were not statistically significant. | Small sample, short follow-up, and participants could use other cosmetics. | Limited human evidence |
| Randomized microneedle patch study | 52 women enrolled across three groups; 50 completed | Plain patch, hexapeptide patch, or a separate growth-factor patch over 29 days | Dissolving hyaluronic-acid patches, with the peptide in one of the three patch types | The peptide patch improved some eye-area wrinkle measurements more than the plain patch. | The study was small and used a different delivery method from a cream. Its text and figure give inconsistent timing for a wrinkle comparison. | Limited human evidence for the tested patch |
| Randomized three-group cream study | 21 women, seven assigned to each cream | Hexapeptide cream, a different peptide cream, or placebo for eight weeks | Creams applied around the eyes | Some participants improved; the authors found no significant difference between the two peptide creams. | Small groups and undisclosed peptide concentration limit interpretation. Paragon Technology and Innovation supported the study. | Preliminary human evidence for the tested creams |
Use context
Reported use context
These schedules describe the specific products studied, not recommendations for other formulations.
Study and label context
Participants applied an emulsion described as containing 10% Argireline, or its placebo, twice daily for four weeks.
The paper does not clarify whether 10% means active peptide or a supplier preparation, and its printed sequence differs from the ingredient specification.Participants applied the assigned serum to each side of the face morning and evening for four weeks.
Both serums contained hyaluronic acids; only one included the peptide.The assigned patch was applied once a week during the 29-day study.
Three groups used different patches; the growth-factor patch was a separate group.The assigned cream was applied around the eyes twice daily for eight weeks.
The paper does not specify the peptide concentration and included only seven participants per group.Cautions
Safety and unknowns
- The cosmetic safety panel's conclusion covered assessed uses up to 0.005%. The available data were insufficient for a safety conclusion above that level.
- The 19-person serum study reported no skin irritation or allergic reactions, but its short duration and small size cannot exclude uncommon reactions.
- In the three-group cream study, one of seven participants using the hexapeptide cream reported itching and two reported stinging. Reactions were also reported with placebo; the study cannot identify the cause.
- Eye-area formulations are intended for the surrounding skin, not automatically for application inside the eye.
Product quality
Product identity and quality
Finished products vary in their other ingredients, delivery systems, and peptide content. A percentage of a diluted ingredient solution is not necessarily the percentage of active peptide in the final product.
Ingredient name
Acetyl hexapeptide-8 and acetyl hexapeptide-3 refer to the same ingredient.
Concentration basis
A supplier solution can contain much less peptide than its stated solution percentage.
Finished formulation
Other ingredients and the delivery system affect tolerability and performance.
Mechanism
How it is proposed to work
The peptide was designed from a portion of SNAP-25. Laboratory work found interference with a protein complex involved in transmitter release.
In a laboratory test on donated skin, most peptide from one oil-in-water emulsion washed off; none was detected in the deeper skin layer or the fluid beneath it.
This result describes one formulation and does not establish delivery for every product.
Details
Technical details
Sources
References
- 1.
American Journal of Clinical Dermatology. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study
doi:10.1007/s40257-013-0009-9 PMID:23417317
A four-week topical study in 60 participants. The paper calls the product argireline but prints a sequence beginning Gly-Glu rather than the Glu-Glu sequence in the ingredient specification. Its 10% concentration basis is also unclear.
- 2.
ExperChem. Acetyl hexapeptide-8 product information
The supplier specification lists the amidated Ac-Glu-Glu-Met-Gln-Arg-Arg sequence and names argireline and acetyl hexapeptide-3 as synonyms.
- 3.
doi:10.3205/iprs000179 PMID:38024099
A double-blind, 19-person split-face serum study found no statistically significant between-side difference.
- 4.
Annals of Dermatology. Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin
doi:10.5021/ad.2019.31.3.263 PMID:33911590
A randomized study enrolled 52 women across three patch groups; 50 completed. The paper describes the hexapeptide patch, growth-factor patch, and plain patch as separate groups, but its text and figure give inconsistent timing for a wrinkle comparison.
- 5.
Journal of Clinical and Aesthetic Dermatology. Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet
PMID:36909866
A randomized eight-week trial assigned seven women to each of three creams. It was funded by Paragon Technology and Innovation; the authors reported no relevant conflicts.
- 6.
PubMed. A synthetic hexapeptide (Argireline) with antiwrinkle activity
doi:10.1046/j.1467-2494.2002.00153.x PMID:18498523
Laboratory mechanism and small cosmetic formulation experiments; the laboratory findings do not establish effects at human neuromuscular junctions.
- 7.
PubMed. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation
doi:10.3109/15569527.2014.894521 PMID:24754410
Diffusion-cell experiments used human cadaver and guinea pig skin and one oil-in-water emulsion.
- 8.
Cosmetic Ingredient Review. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics
doi:10.1177/10915818251340391 PMID:40673537
The panel assessed acetyl hexapeptide-8 amide, synonymous with acetyl hexapeptide-8, in specified cosmetic uses.
- 9.
FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)
A product's intended use affects its US regulatory classification.